The Bethesda System for Reporting Thyroid Cytopathology explained for practitioners: Frequently Asked Questions.

Related Articles

The Bethesda System for Reporting Thyroid Cytopathology explained for practitioners: Frequently Asked Questions.

Thyroid. 2018 Mar 28;:

Authors: Bongiovanni M, Papadakis GE, Rouiller N, Marino L, Lamine F, Bisig B, Ziadi S, Sykiotis GP

Abstract
The recent update of the Bethesda system for reporting thyroid cytology (TBSRTC) is a very important development in the evaluation of thyroid nodules. Clinical experience and scientific literature both show that practitioners performing thyroid FNA are accustomed to basing the clinical management of patients on reports using TBSRTC. Specifically, clinicians are familiar with the per cent risk of malignancy (ROM) corresponding to each TBSRTC diagnostic category (DC), as well as with the respective recommendation for clinical management. However, most clinicians are much less familiar with the specific considerations that lie between a specific DC, on the one end, and the respective ROM and associated management recommendation, on the other end. A deeper understanding of the system can enlighten the clinician's thinking about the specific nodule under examination and can guide the decision-making process in a more meaningful way. Such an understanding can only be developed via close, two-way communication between cytopathologists and clinicians. Through this type of interaction in our tertiary medical center, we identified a set of recurring issues of particular importance for clinical practice, which we report here in the form of 16 Frequently Asked Questions (FAQ) posed by the clinician to the cytopathologist. For each FAQ, we provide an answer based on the literature, our experience, the new version of TBSRTC and the new World Health Organization classification of tumors of endocrine organs.

PMID: 29591914 [PubMed - as supplied by publisher]

https://ift.tt/2uujlSE